<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231006</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-218-19</org_study_id>
    <nct_id>NCT04231006</nct_id>
  </id_info>
  <brief_title>Salvage HDR for Locally Recurrent Prostate Cancer</brief_title>
  <acronym>PROSALBRA</acronym>
  <official_title>Salvage High Dose Rate Brachytherapy for Local Recurrence in Prostate Cancer: A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study offers focal salvage brachytherapy for prostate cancer patients with a local
      recurrence after primary defintive radiotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to examine the efficacy and toxicity of focal salvage high dose rate
      brachytherapy (HDR BT) for patients with locally recurrent prostate cancer after definitive
      external beam radiotherapy. Furthermore, the investigators want to assess, whether it is
      feasible to perform salvage HDR BT as a focal treatment based on multiparametric (mp) pelvine
      MRI and PSMA PET/CT.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2035</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to castration-resistant prostate cancer</measure>
    <time_frame>10 years</time_frame>
    <description>The time from intervention until the prostate cancer becomes castration resistant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erectile dysfunction</measure>
    <time_frame>5 years</time_frame>
    <description>Erectile dysfunction as reported by patients in CTCAE PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary symptoms</measure>
    <time_frame>5 years</time_frame>
    <description>Urinary symptoms as reported by patients in CTCAE PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel symptoms</measure>
    <time_frame>5 years</time_frame>
    <description>Bowel symptoms as reported by patients in CTCAE PRO</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High dose rate brachytherapy</intervention_name>
    <description>High dose rate brachytherapy will be delivered to the site of recurrence within the prostate gland based on MRI and PSMA PET/CT</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man ≥ 18 years, who had definitive EBRT or BT for prostate cancer T1-3b, N0-1, M0

          -  ≥ 2 years since the end of primary radiotherapy

          -  PSA recurrence Phoenix criteria (nadir + 2)

          -  No evidence of regional lymph nodes or distant metastases on PSMA PET/CT

          -  MRI guided biopsy-proven local recurrence of adenocarcinoma in the prostate gland or
             seminal vesicles

          -  GTV identifiable on mpMRI

          -  No current endocrine therapy

          -  Plasma testosterone ≥1.75 nm/l

          -  PSA doubling time ≥ 6 months and ≤ 24 months

          -  Performance status 0-1

          -  DAN PSS score ≤ 20

          -  Maximal urinary flow ≥ 10 ml/s

          -  Life expectancy &gt; 5 years

          -  PSA ≤ 10 ug/L at recurrence

        Exclusion Criteria:

          -  Pubic arc interference or major calcifications within the prostate gland.

          -  Contraindication for spinal or general anaesthesia.

          -  Conditions indicating that the patient cannot go through the radiation therapy or
             follow-up, or a condition where the treating oncologist thinks the patient should not
             participate in the trial, for example due to language problems.

          -  Inflammatory bowel disease

          -  Contraindications to 3T MRI

          -  eGFR &lt; 30 ml/min

          -  ≥ Gr 3 urinary toxicity at baseline as assessed by CTCAE 4
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simon Buus, MD</last_name>
    <phone>+4540465291</phone>
    <email>simbuu@rm.dk</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Simon Buus</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

